"A PHASE III, MULTICENTER,RANDOMISED, DOUBLEBLIND,PLACEBOCONTROLLEDSTUDY OF ATEZOLIZUMAB (ANTI−PDL1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER"
2020-07-04
عنوان الدراسة
"A PHASE III, MULTICENTER,RANDOMISED, DOUBLEBLIND,PLACEBOCONTROLLEDSTUDY OF ATEZOLIZUMAB (ANTI−PDL1 ANTIBODY) IN COMBINATION WITH PACLITAXEL COMPARED WITH PLACEBO WITH PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED INOPERABLE LOCALLY ADVANCED OR METASTATIC TRIPLE NEGATIVE BREAST CANCER"
داعم الدراسة
Roche
دواء الدراسة
ATEZOLIZUMAB / PACLITAXEL
رقم بروتوكول الدراسة
MO39196
حالة الدراسة
Ongoing
موقع الدراسة
International Medical Center (Jeddah), King Fahad Specialist Hospital (Dammam), King Fahad Medical City (Riyadh)
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。